MTOR inhibitor-based combination therapies for pancreatic cancer-Reference-Cited by-同舟云学术

MTOR inhibitor-based combination therapies for pancreatic cancer

Published:2018-01-02 Issue:3 Volume:118 Page:366-377
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Hassan Zonera,Schneeweis Christian,Wirth Matthias,Veltkamp Christian,Dantes Zahra,Feuerecker Benedikt,Ceyhan Güralp O,Knauer Shirley K,Weichert Wilko,Schmid Roland M,Stauber Roland,Arlt Alexander,Krämer Oliver H,Rad Roland,Reichert Maximilian,Saur Dieter,Schneider Günter

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2017421.pdf

Reference58 articles.

1. Afgan E, Baker D, van den Beek M, Blankenberg D, Bouvier D, Cech M, Chilton J, Clements D, Coraor N, Eberhard C, Gruning B, Guerler A, Hillman-Jackson J, Von Kuster G, Rasche E, Soranzo N, Turaga N, Taylor J, Nekrutenko A, Goecks J (2016) The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. Nucleic Acids Res 44 (W1): W3–W10.

2. Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes C, Engelman JA, Bardeesy N (2015) Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res 21 (2): 396–404.

3. Babicki S, Arndt D, Marcu A, Liang Y, Grant JR, Maciejewski A, Wishart DS (2016) Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res 44 (W1): W147–W153.

4. Baer R, Cintas C, Dufresne M, Cassant-Sourdy S, Schonhuber N, Planque L, Lulka H, Couderc B, Bousquet C, Garmy-Susini B, Vanhaesebroeck B, Pyronnet S, Saur D, Guillermet-Guibert J (2014) Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110alpha. Genes Dev 28 (23): 2621–2635.

5. Bai Y, Kim JY, Watters JM, Fang B, Kinose F, Song L, Koomen JM, Teer JK, Fisher K, Chen YA, Rix U, Haura EB (2014) Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Cancer Res 74 (24): 7217–7228.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Copy Number Variations in Pancreatic Cancer: From Biological Significance to Clinical Utility;International Journal of Molecular Sciences;2023-12-27

2. SHP2 clinical phenotype, cancer, or RASopathies, can be predicted by mutant conformational propensities;Cellular and Molecular Life Sciences;2023-12-12

3. Gene Expression Profile Prediction under Drug Action Based on Generative Adversarial Networks;2023 IEEE International Conference on Bioinformatics and Biomedicine (BIBM);2023-12-05

4. Juglone Effects by Dual Way on mTOR Gene Expression, Which Plays Central Role in Cell Growth, Survival and Metabolism, in PANC-1 and BxPC-3 Pancreatic Cancer Cell Lines;Genel Tıp Dergisi;2023-08-31

5. Exploiting Vitamin D Receptor and Its Ligands to Target Squamous Cell Carcinomas of the Head and Neck;International Journal of Molecular Sciences;2023-02-28